These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 704717)

  • 1. Clinical Research Centre Division of Psychiatry 1974-1977.
    Crow TJ
    Psychol Med; 1978 Aug; 8(3):515-23. PubMed ID: 704717
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 3. The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia.
    Prades R; Munarriz-Cuezva E; Urigüen L; Gil-Pisa I; Gómez L; Mendieta L; Royo S; Giralt E; Tarragó T; Meana JJ
    Eur Neuropsychopharmacol; 2017 Feb; 27(2):180-191. PubMed ID: 27986355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenergic receptors in the nucleus accumbens shell differentially modulate dopamine and acetylcholine receptor-mediated turning behaviour.
    Ikeda H; Moribe S; Sato M; Kotani A; Koshikawa N; Cools AR
    Eur J Pharmacol; 2007 Jan; 554(2-3):175-82. PubMed ID: 17113067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of psychotropic drugs on research in psychiatry.
    Davis JM; Dysken MW
    Minn Med; 1979 Feb; 62(2):109-16. PubMed ID: 431510
    [No Abstract]   [Full Text] [Related]  

  • 6. [Methodological approaches to the assessment of cognitive symptoms during psychopharmacotherapy].
    Tsygankov BD; Khananova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(10):66-71. PubMed ID: 21510452
    [No Abstract]   [Full Text] [Related]  

  • 7. Loss of the Kamin blocking effect in acute but not chronic schizophrenics.
    Jones SH; Gray JA; Hemsley DR
    Biol Psychiatry; 1992 Nov; 32(9):739-55. PubMed ID: 1360261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia: D4 receptor elevation. What does it mean?
    Seeman MV
    J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
    [No Abstract]   [Full Text] [Related]  

  • 9. Tyrosine transport in schizophrenia.
    Wiesel FA; Venizelos N; Bjerkenstedt L; Hagenfeldt L
    Schizophr Res; 1994 Oct; 13(3):255-8. PubMed ID: 7841139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prolactin response in clinical psychiatry.
    Gruen PH
    Med Clin North Am; 1978 Mar; 62(2):409-24. PubMed ID: 347199
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence against dopaminergic and further support for alpha-adrenergic receptor involvement in the pineal phosphatidylinositol effect.
    Nijjar MS; Smith TL; Hauser G
    J Neurochem; 1980 Apr; 34(4):813-21. PubMed ID: 6244362
    [No Abstract]   [Full Text] [Related]  

  • 13. Receptor supersensitivity in mental disease.
    Westermann KH; Funk KF
    Agressologie; 1981 Nov; 22(E):33-5. PubMed ID: 7332048
    [No Abstract]   [Full Text] [Related]  

  • 14. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical Improvement of Schizophrenic Symptoms by a Dopaminergic Agonist: An Example of Personalized Psychiatry in a Copy Number Variation-Carrying Patient.
    Alexandre C; Chaumette B; Martinez G; Christa L; Dupont JM; Kebir O; Gaillard R; Amado I; Krebs MO
    Biol Psychiatry; 2016 Aug; 80(4):e21-e23. PubMed ID: 26602590
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurocognitive impairment in schizophrenia and how it affects treatment options.
    Bilder RM
    Can J Psychiatry; 1997 Apr; 42(3):255-64. PubMed ID: 9114941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of clozapine on neurocognition: an overview.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():88-90. PubMed ID: 7525543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenergic targets for the treatment of cognitive deficits in schizophrenia.
    Arnsten AF
    Psychopharmacology (Berl); 2004 Jun; 174(1):25-31. PubMed ID: 15205875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D1 and D2 and D3.
    Healy D
    Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592
    [No Abstract]   [Full Text] [Related]  

  • 20. [Neuroleptics and nicotine].
    Erdmann R
    Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.